Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TARS Catalyst Timeline
Dated clinical, regulatory and corporate events for Tarsus Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tarsus Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How TARS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | TP-03 (Ersa) | Phase 2a topline data readout | Phase 2a |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| XDEMVY |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TP-06 Small MoleculesNCT07886268 | Persistent Corneal Epithelial Defect | Phase 2 | RECRUITING | 32 | Jul 7, 2028 | ||||||
| TP-05 Small MoleculesNCT07562087 | Lyme Disease | Phase 2 | ACTIVE NOT_RECRUITING | 722 | Dec 1, 2027 | ||||||
| Lotilaner, 2.0% Small MoleculesNCT07443202 | Ocular Rosacea | Phase 2 | ENROLLING BY_INVITATION | 155 | Dec 31, 2027 | ||||||
| IRX-101 Medical DevicesNCT05747430 | Retinal Disease | Phase 3 | COMPLETED | 395 | Mar 31, 2026 | ||||||
| Lotilaner, 2.0% Small MoleculesNot countedNCT05838170 | Papulopustular Rosacea | Phase 2 | COMPLETED | 37 | Nov 13, 2023 | ||||||
| Xdemvy Small MoleculesMarketedNCT04784091 | Blepharitis | Approved | COMPLETED | 833 | May 9, 2022 | ||||||
| Xdemvy Small MoleculesNot countedNCT05454956 | Meibomian Gland Dysfunction | Phase 2 | COMPLETED | 39 | May 18, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every TARS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TP-05 | Lyme disease prevention | Phase 2a | 2024-02-22 | Day 1: high dose mortality 97.0%, low dose mortality 92.0%, placebo mortality 5.0%; Day 30: high dose mortality 89.0%, low dose mortality 91.0%, placebo mortality 9.0%Read More | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Azamian Bobak R.Director, Officer (President/CEO and Board Chair) | Sell | -10,000 817,991 held | $80.31 | 11/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TARS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 4.9 % (44.1 %) | 299.25 M | 3.81 M | 3.82% ( 140.00 K) |
Ownership Trends
TARS Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TARS ranks across every disease it competes in
TARS News
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals announced its participation in several upcoming investor conferences. Notable events include the Guggenheim 3rd Annual Healthcare Conference on November 10th and the Jefferies Global Healthcare Conference on November 18th and 19th. Management will also engage in a fireside chat at the Piper Sandler Conference on December 1st.
Read more →Tarsus Reports Third Quarter 2026 Financial Results
Tarsus Pharmaceuticals reported record net product sales of $194.6 million for Q3 2026, marking a 64% increase year-over-year. The company surpassed one million bottles of XDEMVY dispensed and achieved over $1 billion in cumulative sales. Despite these successes, Tarsus faced a net loss of $668.3 million, largely due to increased R&D and SG&A expenses.
Read more →Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Tarsus Pharmaceuticals will host a live webcast on November 3, 2026, to report its third quarter 2026 financial results and provide a corporate update. The company is advancing its pipeline, including treatments for ocular rosacea and Lyme disease. XDEMVY is already FDA approved for treating Demodex blepharitis.
Read more →Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Tarsus Pharmaceuticals announced the appointment of Neera Clase as Chief Commercial Officer, effective November 1, 2026. Clase, who has been with Tarsus since July 2026, will lead the commercial strategy focusing on expanding the reach of XDEMVY. She aims to leverage her experience to enhance Tarsus's pipeline, which includes several investigational treatments.
Read more →Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
Tarsus Pharmaceuticals plans to present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting, focusing on Demodex blepharitis, ocular rosacea, and the real-world impact of XDEMVY. These findings aim to enhance understanding and management of these conditions among eye care professionals. The conference will take place from September 30 to October 3 in Anaheim, California.
Read more →Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, enhancing its focus on eye care. The acquisition adds ALK-001, an investigational treatment for Stargardt disease, which has received multiple FDA designations. Tarsus aims to advance the NORTHSTAR Phase 3 trial for ALK-001, with topline data expected in 2029.
Read more →Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Tarsus reported strong financial results for the second quarter of 2026, with net product sales of $173.9 million, reflecting a 69% increase year-over-year. The company has raised its full-year sales guidance to between $685 million and $705 million. Additionally, Tarsus is pursuing the acquisition of Alkeus Pharmaceuticals to further develop its retina pipeline, which includes a Phase 3 study.
Read more →Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals has announced a successful $125 million private placement equity financing. The deal includes participation from existing and new investors, aimed at funding clinical development and other corporate purposes. The financing is set to close on August 7, 2026, subject to customary conditions.
Read more →Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Tarsus Pharmaceuticals has announced its acquisition of Alkeus Pharmaceuticals, focusing on gildeuretinol (ALK-001), an investigational oral therapy for Stargardt disease. This acquisition aims to enhance Tarsus' position in the retina market and is backed by positive clinical findings. The deal includes a $450 million upfront payment and potential future milestones. Top-line data from the Phase 3 NORTHSTAR trial is expected in 2029.
Read more →Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Tarsus Pharmaceuticals will report its second quarter 2026 financial results on August 6, 2026. The company will host a live webcast at 5:00 a.m. PT to provide updates. Tarsus focuses on innovative treatments in eye care and other therapeutic areas, with products in various stages of development.
Read more →Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
Tarsus Pharmaceuticals announced the departure of Chief Commercial Officer Aziz Mottiwala, who will become CEO of a medical device company. Neera Clase has been appointed as Interim Chief Commercial Officer. This transition occurs as Tarsus enters a growth phase following the successful launch of XDEMVY and the acquisition of iRenix Medical, strengthening its position in eye care.
Read more →Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
Tarsus Pharmaceuticals agreed to acquire iRenix Medical for an upfront payment of approximately $75 million. The deal includes potential milestone payments of up to $490 million. Tarsus will advance the late-stage asset IRX-101 through a Phase 3 study starting in 2027. The company plans to announce results from this trial in 2028.
Read more →Tarsus to Participate in Upcoming June 2026 Investor Conferences
Tarsus Pharmaceuticals, Inc. announced its participation in several upcoming investor conferences in June 2026. The company aims to showcase its advancements in eye care and infectious disease prevention. Tarsus is also progressing its pipeline, including FDA-approved XDEMVY and other treatments in Phase 2 development.
Read more →Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharmaceuticals has partnered with John Cena to raise awareness about Demodex blepharitis, a common eyelid disease affecting around 25 million Americans. Cena shares his personal experience with the condition and the FDA-approved treatment, XDEMVY. The campaign aims to encourage individuals to prioritize their eye health and seek proper diagnosis and treatment.
Read more →Tarsus to Participate in Upcoming May 2026 Investor Conferences
Tarsus Pharmaceuticals, Inc. has announced its participation in upcoming investor conferences. The company is focused on advancing its pipeline, which includes FDA-approved XDEMVY for Demodex blepharitis and other treatments in development. These efforts highlight Tarsus's commitment to addressing high unmet needs in eye care and infectious disease prevention.
Read more →Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals reported strong first quarter 2026 financial results, with XDEMVY sales exceeding $145 million, marking an 85% increase year-over-year. The company reaffirmed its full-year sales guidance of $670-700 million and highlighted the growing adoption of XDEMVY among eye care professionals. Additionally, Tarsus initiated a Phase 2 trial for TP-05, an investigational oral tablet aimed at preventing Lyme disease.
Read more →Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Tarsus Pharmaceuticals, Inc. will host a live webcast on May 6, 2026, to report its first quarter financial results and provide a corporate update. The company is focused on innovative treatments in eye care and infectious disease prevention. Tarsus has FDA approval for its product XDEMVY and is developing additional therapies in Phase 2.
Read more →